Paez JG, Jänne PA, Lee JC, Tracy S, Greulich H, Gabriel S, et al. EGFR mutations in lung cancer: correlation with clinical response to gefitinib therapy. Science. 2004;304(5676):1497–500.
Lynch TJ, Bell DW, Sordella R, Gurubhagavatula S, Okimoto RA, Brannigan BW, et al. Activating mutations in the epidermal growth factor receptor underlying responsiveness of non-small-cell lung cancer to gefitinib. N Engl J Med. 2004;350(21):2129–39.
Zhou C, Wu Y-L, Chen G, Feng J, Liu X-Q, Wang C, et al. Erlotinib versus chemotherapy as first-line treatment for patients with advanced EGFR mutation-positive non-small-cell lung cancer (OPTIMAL, CTONG-0802): a multicentre, open-label, randomised, phase 3 study. Lancet Oncol. 2011;12(8):735–42.
Han J-Y, Park K, Kim S-W, Lee DH, Kim HY, Kim HT, et al. First-SIGNAL: first-line single-agent iressa versus gemcitabine and cisplatin trial in never-smokers with adenocarcinoma of the lung. J Clin Oncol. 2012;30(10):1122–8.
Mok TS, Wu Y-L, Thongprasert S, Yang C-H, Chu D-T, Saijo N, et al. Gefitinib or carboplatin-paclitaxel in pulmonary adenocarcinoma. N Engl J Med. 2009;361(10):947–57.
Maemondo M, Inoue A, Kobayashi K, Sugawara S, Oizumi S, Isobe H, et al. Gefitinib or chemotherapy for non-small-cell lung cancer with mutated EGFR. N Engl J Med. 2010;362(25):2380–8.
Mitsudomi T, Morita S, Yatabe Y, Negoro S, Okamoto I, Tsurutani J, et al. Gefitinib versus cisplatin plus docetaxel in patients with non-small-cell lung cancer harbouring mutations of the epidermal growth factor receptor (WJTOG3405): an open label, randomised phase 3 trial. Lancet Oncol. 2010;11(2):121–8.
Wu S-G, Shih J-Y. Management of acquired resistance to EGFR TKI-targeted therapy in advanced non-small cell lung cancer. Mol Cancer. 2018;17(1):38.
Tang Z-H, Lu J-J. Osimertinib resistance in non-small cell lung cancer: mechanisms and therapeutic strategies. Cancer Lett. 2018;420:242–6.
Rotow J, Bivona TG. Understanding and targeting resistance mechanisms in NSCLC. Nat Rev Cancer. 2017;17(11):637–58.
Hosomi Y, Morita S, Sugawara S, Kato T, Fukuhara T, Gemma A, et al. Gefitinib alone versus gefitinib plus chemotherapy for non-small-cell lung cancer with mutated epidermal growth factor receptor: NEJ009 study. J Clin Oncol. 2020;38(2):115–23.
Saito H, Fukuhara T, Furuya N, Watanabe K, Sugawara S, Iwasawa S, et al. Erlotinib plus bevacizumab versus erlotinib alone in patients with EGFR-positive advanced non-squamous non-small-cell lung cancer (NEJ026): interim analysis of an open-label, randomised, multicentre, phase 3 trial. Lancet Oncol. 2019;20(5):625–35.
Oizumi S, Sugawara S, Minato K, Harada T, Inoue A, Fujita Y, et al. Updated survival outcomes of NEJ005/TCOG0902: a randomised phase II study of concurrent versus sequential alternating gefitinib and chemotherapy in previously untreated non-small cell lung cancer with sensitive EGFR mutations. ESMO Open. 2018;3(2):e000313.
Hanania AN, Mainwaring W, Ghebre YT, Hanania NA, Ludwig M. Radiation-induced lung injury: assessment and management. Chest. 2019;156(1):150–62.
Bledsoe TJ, Nath SK, Decker RH. Radiation pneumonitis. Clin Chest Med. 2017;38(2):201–8.
Xia B, Zhang S, Ma S. Management of non-small cell lung cancer with mutation: the role of radiotherapy in the era of tyrosine kinase inhibitor therapy-opportunities and challenges. J Thorac Dis. 2017;9(9):3385–93.
Peters S, Felip E, Dafni U, Belka C, Guckenberger M, Irigoyen A, et al. Safety evaluation of nivolumab added concurrently to radiotherapy in a standard first line chemo-radiotherapy regimen in stage III non-small cell lung cancer-The ETOP NICOLAS trial. Lung Cancer. 2019;133:83–7.
Zhang Y, Wang W, Xu X, Li Y, Zhang H, Li J, et al. Impact of radiotherapy pattern on the prognosis of stage iv lung adenocarcinomas harboring EGFR mutations. Cancer Manag Res. 2021;13:3293–301.
Lehman M, Bernard A, See A, King M, Michael M. A randomized phase 3 trial of palliative radiation therapy versus concurrent chemotherapy and palliative radiation therapy in patients with good performance status, locally advanced, or metastatic non-small cell lung cancer with symptoms due to intrathoracic disease who are not suitable for radical chemo-radiation therapy: results of the trans-tasman radiation oncology group 11.03 trial. Pract Radiat Oncol. 2021;11(4):252–63.
Toy E, Macbeth F, Coles B, Melville A, Eastwood A. Palliative thoracic radiotherapy for non-small-cell lung cancer: a systematic review. Am J Clin Oncol. 2003;26(2):112–20.
Saunders MI. Programming of radiotherapy in the treatment of non-small-cell lung cancer–a way to advance care. Lancet Oncol. 2001;2(7):401–8.
Katsui K, Ogata T, Watanabe K, Katayama N, Kuroda M, Kiura K, et al. Radiation pneumonitis after definitive concurrent chemoradiotherapy with cisplatin/docetaxel for non-small cell lung cancer: analysis of dose-volume parameters. Cancer Med. 2020;9(13):4540–9.
Noronha V, Patil VM, Joshi A, Menon N, Chougule A, Mahajan A, et al. Gefitinib versus gefitinib plus pemetrexed and carboplatin chemotherapy in -mutated lung cancer. J Clin Oncol. 2020;38(2):124–36.
Zheng L, Wang Y, Xu Z, Yang Q, Zhu G, Liao X-Y, et al. Concurrent EGFR-TKI and thoracic radiotherapy as first-line treatment for stage IV Non-small cell lung cancer harboring EGFR active mutations. Oncologist. 2019;24(8):1031-e612.
Stephens SJ, Moravan MJ, Salama JK. Managing patients with oligometastatic non-small-cell lung cancer. J Oncol Pract. 2018;14(1):23–31.
Zhou Y, Yu F, Zhao Y, Zeng Y, Yang X, Chu L, et al. A narrative review of evolving roles of radiotherapy in advanced non-small cell lung cancer: from palliative care to active player. Transl Lung Cancer Res. 2020;9(6):2479–93.
Timmerman RD, Kavanagh BD, Cho LC, Papiez L, Xing L. Stereotactic body radiation therapy in multiple organ sites. J Clin Oncol. 2007;25(8):947–52.
Suh Y-G, Cho J. Local ablative radiotherapy for oligometastatic non-small cell lung cancer. Radiat Oncol J. 2019;37(3):149–55.
Tang Y, Xia B, Xie R, Xu X, Zhang M, Wu K, et al. Timing in combination with radiotherapy and patterns of disease progression in non-small cell lung cancer treated with EGFR-TKI. Lung Cancer. 2020;140:65–70.
Westover KD, Loo BW, Gerber DE, Iyengar P, Choy H, Diehn M, et al. Precision Hypofractionated radiation therapy in poor performing patients with non-small cell lung cancer: phase 1 dose escalation trial. Int J Radiat Oncol Biol Phys. 2015;93(1):72–81.
Wang X, Zeng Z, Cai J, Xu P, Liang P, Luo Y, et al. Efficacy and acquired resistance for EGFR-TKI plus thoracic SBRT in patients with advanced EGFR-mutant non-small-cell lung cancer: a propensity-matched retrospective study. BMC Cancer. 2021;21(1):482.
留言 (0)